

# Investigator Curriculum Vitae

This template may be used by Sponsors of clinical trials as part of the application dossier.

EU CT number: N.A.

A separate document should be completed and submitted for each site.

This template has been developed and endorsed by the EU Clinical Trials Expert Group to comply with Regulation (EU) No. 536/2014 Clinical Trials on Medicinal Products for Human Use.

## Personal Information

Name: **ANDREA BERNARDELLI**  
Title: MD  
Profession: Medical Doctor  
Current position: Hematologist

## Professional Registration<sup>i</sup>

Registration number: 09147  
Registration body: Order of Physicians of the Province of Verona  
Registration expiry date (if applicable): n.a.  
Registration state/province (if applicable): Verona

## Education and Qualifications<sup>ii</sup>

| Institution name            | Qualification                         | Year        |
|-----------------------------|---------------------------------------|-------------|
| <b>University of Verona</b> | <b>Degree in Medicine and Surgery</b> | <b>2018</b> |
| <b>University of Verona</b> | <b>Specialization in Hematology</b>   | <b>2022</b> |

## Investigator Curriculum Vitae

### Current employment

|                      |                                                                                              |
|----------------------|----------------------------------------------------------------------------------------------|
| Institution name:    | <b>University of Verona</b>                                                                  |
| Department:          | <b>Section of Hematology, Department of Engineering for Innovation Medicine</b>              |
| Institution address: | <b>Hematology Unit, Policlinico G.B. Rossi, Piazzale L.A. Scuro, 10, 37134 Verona, Italy</b> |
| Telephone number:    | <b>+390458124420</b>                                                                         |
| E-mail address:      | <b>andrea.bernardelli@aovr.veneto.it</b>                                                     |

### Professional experience<sup>iii</sup>

| Position                               | Institution name and department                                                                       | Start year  | End year       |
|----------------------------------------|-------------------------------------------------------------------------------------------------------|-------------|----------------|
| <b>Hematologist</b>                    | <b>University of Verona, Section of Hematology, Department of Engineering for Innovation Medicine</b> | <b>2022</b> | <b>ongoing</b> |
| <b>Residency Program in Hematology</b> | <b>University of Verona, Section of Hematology, Department of Engineering for Innovation Medicine</b> | <b>2018</b> | <b>2022</b>    |

### Relevant clinical trial/study experience<sup>iv</sup>

| Investigator role      | Therapeutic area                                                             | Type of trial        | Year started | Phase      | Ongoing |
|------------------------|------------------------------------------------------------------------------|----------------------|--------------|------------|---------|
| Principal Investigator | Hodgkin lymphoma                                                             | Other research study | 2023         | Other      | Yes     |
| Principal Investigator | Systemic mastocytosis                                                        | Interventional Trial | 2023         | Phase II   | Yes     |
| Principal Investigator | MDS                                                                          | Other research study | 2023         | Other      | Yes     |
| Sub Investigator       | mantle cell lymphoma                                                         | Interventional Trial | 2022         | Phase II   | Yes     |
| Sub Investigator       | mantle cell lymphoma                                                         | Interventional Trial | 2022         | Phase III  | Yes     |
| Sub Investigator       | diffuse large B-cell lymphoma                                                | Interventional Trial | 2021         | Phase III  | Yes     |
| Sub Investigator       | aggressive B-cell lymphoma, FL, MZL, MCL, peripheral T-cell lymphoma and CHL | Interventional Trial | 2021         | Phase I/II | Yes     |

## Investigator Curriculum Vitae

### Training

#### Research training (including GCP)

#### Institution name

#### Year obtained

ICH GOOD CLINICAL PRACTICE

GLOBAL HEALTH TRAINING  
CENTRE

14/03/2023

#### Date completed<sup>5</sup>:

30 Jan 2024

AZIENDA OSPEDALIERA UNIVERSITARIA  
INTEGRATA - VERONA  
Policlinico G.B. Rossi  
Dott. Andrea Bernardelli  
Iscri. Ordine Medici n° VR09148

<sup>5</sup> The CTR does not require signing individual documents in the clinical trial application – a request for signature could however be subject to national legislation.

<sup>i</sup> As per national legislation

<sup>ii</sup> Relevant to be an investigator

<sup>iii</sup> This should cover the preceding 10 years as a maximum

<sup>iv</sup> Idem

<sup>v</sup> The CTR does not require signing individual documents in the clinical trial application – a request for signature could however be subject to national legislation.